“…Normal renal parenchyma was used as a negative control. As a positive control, the section of tumor tissue that was cytologically diagnosed as Xp11 translocation carcinoma was used …”
Section: Methodsmentioning
confidence: 99%
“…FISH analyses were carried out using a custom‐made dual‐color break‐apart DNA probe (Chromosome Science Labo, Sapporo, Japan) as previously reported . This rearrangement probe was created using bacterial artificial chromosome clones (centromeric [RP11‐57A11 + RP11‐211H18] and telomeric [RP11‐343N17 + RP11‐735G22]).…”
Section: Methodsmentioning
confidence: 99%
“…As a positive control, the section of tumor tissue that was cytologically diagnosed as Xp11 translocation carcinoma was used. 13 FISH probe design and protocol FISH analyses were carried out using a custom-made dualcolor break-apart DNA probe (Chromosome Science Labo, Sapporo, Japan) as previously reported. 13,14 This rearrangement probe was created using bacterial artificial chromosome clones (centromeric [RP11-57A11 + RP11-211H18] and telomeric [RP11-343N17 + RP11-735G22]).…”
Objectives: To determine the rate and clinicopathological features of Xp11.2 translocation carcinoma using immunostaining of transcription factor E3 and fluorescence in situ hybridization analysis. Methods: We evaluated 638 patients with renal cell carcinoma treated at Sapporo Medical University Hospital, Sapporo, Japan, from 1990 to 2009 by reviewing all hematoxylin-eosin-stained sections and carrying out immunostaining of transcription factor E3 for all cases. Fluorescence in situ hybridization analysis was carried out for patients with positive immunostaining or with findings suspicious for Xp11.2 translocation carcinoma on hematoxylin-eosin-stained sections. In this analysis, we set a cut-off level for split signals of at least 10% of nuclei. Results: Of the 631 patients, 20 (3.2%) were positive for immunostaining. Finally, five patients were diagnosed with Xp11.2 translocation carcinoma (0.8%). Four of these patients were female and aged less than 50 years, and three cases were diagnosed as stage IV with multiple regional lymph nodal or visceral metastases. The positive predictive value of immunostaining was 25%. Conclusion: Patients with Xp11 translocation renal cell carcinoma tend to be younger, more frequently female and diagnosed at a more advanced stage. Immunostaining followed by fluorescence in situ hybridization analysis is an accurate and cost-effective approach for diagnosis of Xp11 translocation renal cell carcinoma.
“…Normal renal parenchyma was used as a negative control. As a positive control, the section of tumor tissue that was cytologically diagnosed as Xp11 translocation carcinoma was used …”
Section: Methodsmentioning
confidence: 99%
“…FISH analyses were carried out using a custom ‐made dual‐color break‐apart DNA probe (Chromosome Science Labo, Sapporo, Japan) as previously reported . This rearrangement probe was created using bacterial artificial chromosome clones (centromeric [RP11‐57A11 + RP11‐211H18] and telomeric [RP11‐343N17 + RP11‐735G22]).…”
Section: Methodsmentioning
confidence: 99%
“…As a positive control, the section of tumor tissue that was cytologically diagnosed as Xp11 translocation carcinoma was used. 13 FISH probe design and protocol FISH analyses were carried out using a custom-made dualcolor break-apart DNA probe (Chromosome Science Labo, Sapporo, Japan) as previously reported. 13,14 This rearrangement probe was created using bacterial artificial chromosome clones (centromeric [RP11-57A11 + RP11-211H18] and telomeric [RP11-343N17 + RP11-735G22]).…”
Objectives: To determine the rate and clinicopathological features of Xp11.2 translocation carcinoma using immunostaining of transcription factor E3 and fluorescence in situ hybridization analysis. Methods: We evaluated 638 patients with renal cell carcinoma treated at Sapporo Medical University Hospital, Sapporo, Japan, from 1990 to 2009 by reviewing all hematoxylin-eosin-stained sections and carrying out immunostaining of transcription factor E3 for all cases. Fluorescence in situ hybridization analysis was carried out for patients with positive immunostaining or with findings suspicious for Xp11.2 translocation carcinoma on hematoxylin-eosin-stained sections. In this analysis, we set a cut-off level for split signals of at least 10% of nuclei. Results: Of the 631 patients, 20 (3.2%) were positive for immunostaining. Finally, five patients were diagnosed with Xp11.2 translocation carcinoma (0.8%). Four of these patients were female and aged less than 50 years, and three cases were diagnosed as stage IV with multiple regional lymph nodal or visceral metastases. The positive predictive value of immunostaining was 25%. Conclusion: Patients with Xp11 translocation renal cell carcinoma tend to be younger, more frequently female and diagnosed at a more advanced stage. Immunostaining followed by fluorescence in situ hybridization analysis is an accurate and cost-effective approach for diagnosis of Xp11 translocation renal cell carcinoma.
“…Often, information on original patients- cell line donors- is fragmentary and more precise characteristics of established cell lines come with time, thanks to cell biology and genetic studies [28, 33]. Most recently, interesting cell lines representing novel RCC subtypes have been established, including NCCFH1 for hereditary papillary renal cell carcinoma type 2 [40] or the S-TFE cell line for Xp11 translocation renal cell carcinoma [41]. In Additional file 1: Table S1, we collected various information available for over 60 cell lines- including the source of starting material, basic genomic data, and database tools that might be useful in designing RCC cell line-based experiments.Fig.…”
Section: Introductionmentioning
confidence: 99%
“…An in vitro model for Xp11.2 translocation carcinoma has recently been established as well. S-TFE cell line is tumorigenic in nude mice and has fused TFE3 and ASPL genes [41]. …”
Cell lines are still a tool of choice for many fields of biomedical research, including oncology. Although cancer is a very complex disease, many discoveries have been made using monocultures of established cell lines. Therefore, the proper use of in vitro models is crucial to enhance our understanding of cancer. Therapeutics against renal cell cancer (RCC) are also screened with the use of cell lines. Multiple RCC in vitro cultures are available, allowing in vivo heterogeneity in the laboratory, but at the same time, these can be a source of errors. In this review, we tried to sum up the data on the RCC cell lines used currently. An increasing amount of data on RCC shed new light on the molecular background of the disease; however, it revealed how much still needs to be done. As new types of RCC are being distinguished, novel cell lines and the re-exploration of old ones seems to be indispensable to create effective in vitro tools for drug screening and more.Electronic supplementary materialThe online version of this article (doi:10.1186/s12943-016-0565-8) contains supplementary material, which is available to authorized users.
The accurate diagnosis of Xp11‐translocation renal cell carcinoma (RCC) in adults is challenging. TFE3 (located on chromosome X) fuses with a partner gene generally located on another chromosome. In rare cases TFE3 may fuse with a neighboring gene: RBM10. Because TFE3 false‐positive immunostaining is a common pitfall in many laboratories, demonstration of the chromosomal rearrangement is required in order to ascertain the diagnosis. Fluorescence in situ hybridization (FISH)—that has been considered as the gold standard method—reaches its limits for detecting small Xp11 paracentric inversions. We performed a comprehensive clinical, histological and genomic study of six novel cases of RCC with RBM10‐TFE3 fusion. Using FISH, TFE3 rearrangement was equivocal in one case and negative in others. RBM10‐TFE3 fusion was discovered using targeted RNA sequencing (RNASeq). As all the previously reported cases (mean age: 50), the six patients were adults (mean age: 42), suggesting an epidemiologic difference between RBM10‐TFE3 RCC and tumors harboring some other partner genes, such as ASPSCR1 that rather occur in children. Array‐comparative genomic hybridization showed several alterations, notably a gain of 17q in four cases with papillary features and loss of 3p in one case with clear cells. Our study demonstrates that, though rare among adult cases of RCC, RBM10‐TFE3 fusion is not exceptional and warrants appropriate molecular detection. Notably, it would be worthy to systemically investigate by RNASeq challenging RCC with type‐2 papillary features and 17q gain.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
